Overview
Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956.
Indication
Liothyronine is officially approved for the following indications: In general terms, exogenous liothyronine is used to replace insufficient hormonal production and restore T3 plasma levels. The lack of liothyronine can be presented as a pale and puffy face, coarse, brittle hair, dry skin, croaky voice and constipation as well as irregular periods, drowsiness, and lethargy. Liothyronine should never be used in the suppression of benign nodules and nontoxic diffuse goiter in iodine-sufficient patients nor in the treatment of hyperthyroidism during the recovery phase of subacute thyroiditis.
Associated Conditions
- Autonomy of thyroid gland
- Hyperthyroidism
- Hypothyroidism
- Myxedema coma
- Thyroid Cancer
- Euthyroid Goitre
- Myxedema pre-coma
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/10/18 | N/A | Not yet recruiting | |||
2022/05/20 | Phase 1 | Active, not recruiting | |||
2022/03/08 | Phase 2 | Completed | Cantonal Hospital Zenica | ||
2021/08/24 | Early Phase 1 | Withdrawn | |||
2021/03/04 | Phase 2 | Completed | |||
2021/02/08 | Phase 2 | Active, not recruiting | Pediatric Brain Tumor Consortium | ||
2021/01/26 | Phase 2 | Not yet recruiting | |||
2020/04/16 | Phase 2 | Terminated | |||
2019/10/04 | Phase 2 | Recruiting | |||
2019/10/02 | Phase 1 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Northwind Pharmaceuticals | 51655-124 | ORAL | 13.5 ug in 1 1 | 1/26/2015 | |
| Acella Pharmaceuticals, LLC | 42192-328 | ORAL | 18 ug in 1 1 | 4/25/2023 | |
| Azurity Pharmaceuticals, Inc. | 24338-006 | ORAL | 4.5 ug in 1 1 | 12/8/2023 | |
| Bryant Ranch Prepack | 71335-0166 | ORAL | 25 ug in 1 1 | 8/14/2019 | |
| Azurity Pharmaceuticals, Inc. | 24338-065 | ORAL | 9 ug in 1 1 | 2/17/2023 | |
| Aidarex Pharmaceuticals LLC | 33261-964 | ORAL | 5 ug in 1 1 | 1/9/2014 | |
| Pfizer Laboratories Div Pfizer Inc | 60793-115 | ORAL | 5 ug in 1 1 | 7/24/2019 | |
| Golden State Medical Supply, Inc. | 51407-385 | ORAL | 25 ug in 1 1 | 10/3/2023 | |
| Biocon Pharma Inc. | 70377-115 | ORAL | 25 ug in 1 1 | 2/23/2024 | |
| Bryant Ranch Prepack | 63629-8265 | ORAL | 2.25 ug in 1 1 | 11/14/2018 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| Tertroxin (South Africa) | 343235 | Medicine | A | 9/10/2020 | |
| TERTROXIN tablets | 12520 | Medicine | A | 8/13/1991 |
Help Us Improve
Your feedback helps us provide better drug information and insights.